BusinessQuiet 86d · day 88
Amylyx upsizes stock offering to $500M after avexitide results
Biotech firm raises capital following positive drug development news, pricing shares at $35.50.
What to know
- Amylyx's stock surged on positive avexitide drug development results, sparking strong investor demand.
- The company upsized its public offering from $350M to $500M and priced shares at $35.50, signaling robust market reception.
- The capital raise supports ongoing drug development and company operations in the competitive biotech sector.
Amylyx Pharmaceuticals Biotech company conducting offering
The record 6 articles and posts · last 30 days